the aid library

Filter

6744

Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes

World Health Organization World Health Organization WHO (2021) C_WHO

Health ministries currently lack effective tools for monitoring and evaluation of schistosomiasis control programmes. Egg detection can be used, but the cost, challenges of obtaining samples, and the need for trained personnel and equipment limit the frequency of monitoring. The purpose of this TPP ... more

Contextual Factors Influencing Modern Contraceptive Use in Nigeria

Ejembi, Clara Ladi, Tukur Dahiru, and Alhaji A. Aliyu ICF International (2015) C2

DHS Working Papers No. 120

Living Conditions among People with Activity Limitations in Zambia: A National Representative Study.

Arne H Eide & ME Loeb SINTEF Health Research (2006) C1

This research report provides results from the study on living conditions among people with disabilities in Zambia. Comparisons are made between individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Zambia are also compar ... more

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Prevenção da potencial transmissão do vírus Zika por via sexual
recommended

Organização Mundial da Saùde (2016) C_WHO

Actualização das orientações provisórias 7 de Junho de 2016

India’s Disability Policy – Analysis of Core Concepts of Human Rights

Jessica O’Dowd, Hasheem Mannan, Joanne McVeigh (2013) C1

Lineamientos para el Manejo Clínico y Operativo de la Tuberculosis Drogorresistente

J. A. Caminero, A. Van Deun, P. I. Fujiwara, et. al Unión Internacional Contra la Tuberculosis y Enfermedades Respiratorias (2013)

International technical guidance on sexuality education. An evidence-informed approach.

UNESCO (2018) CC

This revised and fully updated edition of the International technical guidance on sexuality education benefits from a new review of the current evidence, and reaffirms the position of sexuality education within a framework of human rights and gender equality. It promotes structured learning about ... more

Toolkit on disability for AFRICA: CULTURE, BELIEFS, AND DISABILITY

United Nations Division for Social Policy Development (DSPD) & United Nations Department of Economic and Social Affairs (DESA) (2016) C1

Module 13

Humanitarian Action for children 2021 - overview

UNICEF (2020) C1

This edition of UNICEF’s annual Humanitarian Action for Children highlights UNICEF’s funding appeal, which sets out an ambitious agenda to address the major challenges facing children and young people living through conflict and crisis. It presents the investments needed in 2021 to save their li ... more

Planetary Health 101 Information and Resources
recommended

Panorma Perspectives (2018) CC

The Panorama Perspectives: Conversations on Planetary Health report series aims to inspire new thinking, conversations, and engagement with planetary health and other integrated concepts. Collaboration and open knowledge sharing across sectors are necessary to solve the complex global health and dev ... more

The global doctor

Willott C et al. UCL Institute for Global Health and Development Education Research Centre, Institute of Education (2012) C2

This report explores the reasons why global health is critical to medicine and what this means for medical education. It argues that an understanding of global health is important for all students and practicing doctors, rather than being an ‘add-on’ or ‘option’ for specialization.

The Global Status Report on Preventing Violence Against Children 2020

UNICEF WHO (2020) C_WHO

As this report shows, reports of child abuse and of children witnessing violence between their parents and caregivers have increased. Ending violence against children is increasingly within our reach. D

Global competency and outcomes framework for universal health coverage

World Health Organization WHO (2022) C_WHO

INDEX-TB GUIDELINES: Evidence Summaries and Guideline Panel Decision Tables Core Group Guideline Meeting

(2016) C1

This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from this meeting

Cours de formation de l’Initiative des hôpitaux « amis des bébés » destiné au personnel des services de maternité : guide du directeur

UNICEF, World Health Organization WHO (2020) C_WHO

Available in English, French and Spanish